Detail of "103222-11-3"

Reference

Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone

Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone. Paz-Bouza, J. I.; Redding, T. W.; Schally, A. V. (Endocr., Polypept. Cancer Inst., Veterans Adm. Med. Cent., New Orleans, LA 70146, USA). Proc. Natl. Acad. Sci. U. S. A. 60599-38-4 and 57773-63-4 which are cas registry numbers are also used here., 84(4), 1112-16 (English) 1987. CODEN: PNASA6. ISSN: 0027-8424. DOCUMENT TYPE: Journal CA Section: 2 (Mammalian Hormones) Section cross-reference(s): 14 Somatostatin analog D-Phe-cyclo(Cys-Tyr-yd-Trp-Lys-Val-Cys)Trp-NH2 (RC-160) [103222-11-3] and [D-Trp6]LH-RH [57773-63-4] were effective antitumor agents in pancreatic ductal adenocarcinoma induced in female Syrian golden hamster by injecting N-nitrosobis(2-oxopropyl)amine (BOP) [60599-38-4] once a week (10 mg/kg) for 18 wk. Microcapsules of RC-160, designed to release a dose of 5 mg/day, were injected twice a mo. and microcapsules of [D-Trp6]LH-RH, calcd. to liberate 25 mg/day, once a month. After 18 wk of BOP administration, the hamsters were divided into 3 groups. Group I consisted of untreated controls, group II was injected with RC-160, and group III was injected with [D-Trp6]LH-RH. A striking decrease in tumor wt. and vol. was obtained in animals treated with [D-Trp6]LH-RH or with the somatostatin analog RC-160. After 45 days of treatment with either analog, the survival rate was higher in groups II and III (70%), as compared with the control group (35%). Studies, done by light microscopy, high- resoln. microscopy, and electron microscopy, showed a decrease in the total no. of cancer cells changes in the epithelium, connective tissue, and cellular organelles in groups II and III treated with the hypothalamic analogs as compared to controls. These results in female hamsters with induced ductal pancreatic tumors confirm and extend findings, obtained in male animals with transplanted tumors. .

Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095)

Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095). Radulovic, Sinisa; Miller, Glenn; Schally, Andrew V. (Endocr., Polypept., Cancer Inst., Veterans Aff. Med. Cent., New Orleans, LA 70146, USA). Cancer Res., 51(21), 6006-9 (English) 1991. CODEN: CNREA8. ISSN: 0008-5472. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Nude mice bearing xenografts of HT-29 human colon cancer cell line were treated for 4 wk with a [D-Trp6] agonist of LH-releasing hormone (LH-RH), somatostatin analog RC-160, and bombesin/gastrin releasing peptide antagonist RC-3095. Slight inhibitory effect of [D-Trp6]-LH-RH microcapsules releasing 25 mg/day on tumor growth was obsd. that could be due to sex steroid deprivation. 138147-78-1 and 103222-11-3 are cas registry numbers of chemicals which are used as reagents here. Microcapsules of RC-160, releasing 50 mg/day, reduced tumor vol. after 21 and 24 days of treatment. RC-3095 at 20 mg/day administered by daily s.c. injections or by continuous infusion using Alzet osmotic minipumps, had the greatest inhibitory effect on tumor growth. Tumor vol., percentage change in tumor vol., and tumor wts. were decreased. .